Oncology Institute (NASDAQ:STLN) Stock Sold Off by Sen. Richard Blumenthal

Senator Richard Blumenthal (Democratic-Connecticut) recently sold part of their stake in Oncology Institute, Inc. (NASDAQ:STLN). In a filing disclosed on October 26th, the Senator disclosed that they had sold between $1,001 and $15,000 in Oncology Institute stock on September 22nd.

Senator Richard Blumenthal also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/23/2026.
• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.

Oncology Institute Trading Down 6.3%

Shares of NASDAQ STLN opened at $6.29 on Tuesday. The firm has a fifty day moving average price of $6.46. Oncology Institute, Inc. has a one year low of $2.32 and a one year high of $7.13. The firm has a market cap of $621.70 million, a price-to-earnings ratio of -20.97 and a beta of 0.39.

Oncology Institute (NASDAQ:STLN) last posted its earnings results on Thursday, August 6th. The company reported ($0.08) earnings per share for the quarter. The firm had revenue of $161.28 million during the quarter, compared to the consensus estimate of $152.80 million. As a group, research analysts expect that Oncology Institute, Inc. will post -0.21 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in Oncology Institute in the second quarter valued at about $961,000. State Street Corp acquired a new position in Oncology Institute during the 2nd quarter worth approximately $8,432,000. Bank of America Corp DE acquired a new position in Oncology Institute during the 2nd quarter worth approximately $2,129,000. Arrowstreet Capital Limited Partnership increased its position in Oncology Institute by 169.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 419,423 shares of the company’s stock worth $1,288,000 after purchasing an additional 263,699 shares in the last quarter. Finally, Cetera Investment Advisers lifted its stake in Oncology Institute by 427.8% in the 1st quarter. Cetera Investment Advisers now owns 128,195 shares of the company’s stock valued at $394,000 after purchasing an additional 103,908 shares during the last quarter. 36.86% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Oncology Institute news, Director Brad Hively sold 298,853 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $6.51, for a total value of $1,945,533.03. Following the sale, the director owned 411,976 shares in the company, valued at $2,681,963.76. This trade represents a 42.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett bought 12,000 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were bought at an average cost of $6.54 per share, for a total transaction of $78,480.00. Following the purchase, the insider owned 10,660,858 shares of the company’s stock, valued at approximately $69,722,011.32. The trade was a 0.11% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 4.40% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on STLN shares. BTIG Research raised their price target on shares of Oncology Institute from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Needham & Company LLC boosted their price objective on shares of Oncology Institute from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. Lake Street Capital initiated coverage on shares of Oncology Institute in a report on Monday, July 6th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Weiss Ratings initiated coverage on shares of Oncology Institute in a research report on Thursday, August 6th. They set a “sell (d-)” rating on the stock. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

About Senator Blumenthal

Richard Blumenthal (Democratic Party) is a member of the U.S. Senate from Connecticut. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Blumenthal (Democratic Party, Working Families Party) ran for re-election to the U.S. Senate to represent Connecticut. He won in the general election on November 8, 2022. Before his election to the Senate, Blumenthal had served as the Connecticut Attorney General since 1991. He served in the Connecticut State Senate from 1987 to 1991 and in the Connecticut House of Representatives from 1984 to 1987. As of a 2014 analysis of multiple outside rankings, Blumenthal is one of the most reliable Democratic votes, meaning he can be considered a safe vote for the Democratic Party in Congress.

Oncology Institute Company Profile

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.